Peyronies Disease Society's News

              peyronies disease society

Survey results on:

Patient reported observations of Intra Lesional Verapamil for the Treatment of Peyronies Disease

The following results were compiled from a web based survey conducted with certain controls in place to maximize the likelihood of accuracy. This survey was conducted in May - June 2006. This survey had limited participation since it was directed only at those patients that had specifically received ILV treatment.

The survey asked patients who had received IVL to report on several components of the treatment including details of the injection protocol, stage of Peyronies Disease being treated, and patient observed results. The full text of the survey will be provided to any medical or research personnel upon request.

ILV Survey Results

Results	What was Affected	PD How Long Before VI	How Many VI	Dosage
improved - moderately	bend,size,erect	6-12 months	10-12	unk
improved - slightly *	bend	6-12 months	4-6	unk
improved - slightly	bend	1-6 months	10-12	10 mg
improved - slightly *	bend	18-24 months	10-12	10 mg
improved - slightly *	bend	1-6 months	4-6	15 mg
none	n/a	6-12 months	4-6	20 mg
none	n/a	1-6 months	10-12	15 & 20 mg
none	n/a	12-18 months	7-9	10 mg
none	n/a	6-12 months	12- or more	10 mg
none *	n/a	6-12 months	7-9	15 mg
none	n/a	6-12 months	7-9	10 mg
worsened - slightly	bend & size	6-12 months	7-9	20 mg
worsened - slightly	bend & size	1-6 months	4-6	10 mg
worsened - slightly	bend & size	1-6 months	10-12	5 & 10 mg
worsened - moderately	bend & size	12-18 months	10-12	10 mg
worsened - greatly	bend	24 + months	10-12	20 mg
worsened - greatly *	bend & size	6-12 months	10-12	20 mg
worsened - greatly	bend & size	1-6 months	4-6	10 mg

18 ILV patients responded

5 (28%) reported some improvement  (4 slight)
6 (33%) reported no change
7 (39%) reported deformity got worse

* indicates non-PDS member

Peyronies Disease Society (PDS) ™